A prodrug form of cidofovir
Related Products
Active Metabolite(s)
13113Cidofovir
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Brincidofovir

Item No. 35062

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
P-[[(1S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]-phosphonic acid, mono[3-(hexadecyloxy)propyl] ester
CAS Number
444805-28-1
Synonyms
  • hexadecyloxypropyl-CDV
  • 1-O-hexadecyloxypropyl Cidofovir
  • CMX001
  • HDP-CDV
  • HDP (S)-HPMPC
Molecular Formula
C27H52N3O7P
Formula Weight
561.7
Purity
≥98%
Formulation (Request formulation change)
A solid
Solubility(Learn about Variance in Solubility)
Ethanol: soluble
λmax
285 nm
SMILES
O=P(OCCCOCCCCCCCCCCCCCCCC)(O)CO[C@H](CO)CN1C(N=C(C=C1)N)=O
InChi Code
InChI=1S/C27H52N3O7P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-19-35-20-16-21-37-38(33,34)24-36-25(23-31)22-30-18-17-26(28)29-27(30)32/h17-18,25,31H,2-16,19-24H2,1H3,(H,33,34)(H2,28,29,32)/t25-/m0/s1
InChi Key
WXJFKKQWPMNTIM-VWLOTQADSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    5 mg

    $83

    Add

    10 mg

    $158

    Add

    25 mg

    $330

    Add

    50 mg

    $620

    Add
    Cayman Chemical
    Neutrophil Biology Wall Poster

    Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.

    DOWNLOAD NOW
    Product Description

    Brincidofovir is a prodrug form of the antiviral and acyclic nucleoside phosphonate cidofovir (Item No. 13113).1 Brincidofovir is converted to cidofovir in MRC-5 human lung fibroblasts. It inhibits CMV, herpes simplex virus 1 (HSV-1), HSV-2, cowpox, and vaccinia virus replication in plaque reduction assays (EC50s = 0.0009, 0.06, 0.08, 0.6, and ~1 µM, respectively). Brincidofovir decreases mortality in mouse models of cowpox or vaccinia virus infections when administered at doses of 6.7 or 5 mg/kg, respectively.2 Formulations containing brincidofovir have been used in the treatment of smallpox disease.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Aldern, K.A., Ciesla, S.L., Winegarden, K.L., et al. Increased antiviral activity of 1-O-hexadecyloxypropyl-[2-14C]cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism. Mol. Pharmacol. 63(3), 678-681 (2003).

    2. Quenelle, D.C., Collins, D.J., Wan, W.B., et al. Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir. Antimicrob. Agents Chemother. 48(2), 404-412 (2004).